skvi-logo-360w-65tDear Members,

Number One: The Market Cap is Far Too Low for What This Company Already Has Become

Skinvisible Pharmaceuticals (SKVI) is not a quick pick for us. It is a Company we know well, and we are happy to share with our membership. While we did discuss over the weekend the opportunities the Company has in markets it is already serving with products at market. That’s both prescription and over-the-counter pharmaceutical products.

Additionally we discussed Skinvisible’s foray into getting its formulation for Netherton Syndrome designated as an “orphan drug” by the Food & Drug Administration (“FDA”) and the European Medicines Agency (“EMA”).  There is an incredible opportunity to make a difference in the lives of the many patients with that affliction.

Here are the two press releases about the efforts Skinvisible is making:

February 23, 2012
SKINVISIBLE FORMULATION SUBMITTED TO EUROPEAN UNION FOR ORPHAN DRUG DESIGNATION

March 23, 2011
SKINVISIBLE SUBMITS INVISICARE FORMULATION FOR FDA ORPHAN DRUG DESIGNATION

Yes, they date back almost one year on one of these and almost two years on the other. It is critical to understand that this is not an overnight process. As they progress through the process, they get ever closer.  Is it a done deal that the company will get the orphan drug designation? No – but these efforts continue. Knowing Skinvisible and its management for over four years, I understand their philosophy on news and when to issue it. They are among the most conservative you will meet. When you see a release from SKVI, it is because the news is totally called for. It is real and it is material.

Obviously if they get this designation in the US or in Europe, it will be huge.  It will not only allow the Company to do more to get this very important drug to the patients that need it most (over time, of course), it will mean that shares of SKVI stock have a greatly enhanced value.

Valuing SKVI Now – Without even considering the potential of an orphan drug designation:

Here is the good part. If you are looking at the math, it is very good. 

  • With the shares outstanding being less than 110 million shares as reported on OTCMarkets.com, the current market cap is less than $3.9 million USD. 
  • The Company has years of audited financials. 
  • The Company has only issued about 55% of the authorized shares, so they are not a Company that attempts to max out the shares to consultants and as bonuses. 
  • They have an incredible patent portfolio that many others would envy.  (Check it out here)
  • The products at market

There is significant reason do believe that someone could potentially come along and make offers on the patents – or even the company. That is always one to watch for.

Please do review our complete profile on Skinvisible!

See it here: http://stockguru.com//skvi/

Thank you,

John Pentony
Publisher, StockGuru.com

MORE INFORMATION ON SKINVISIBLE:

skvi-logo-360w-65t

Skinvisible Pharmaceuticals, Inc. (OTCBB: SKVI)

CORPORATE CONTACT:

Doreen McMorran
Skinvisible Pharmaceuticals, Inc.
Phone: 702-433-7154
Email: [email protected]

 

On The Web:

Skinvisible.com

Invisicare.com

Disclosures: We hold no shares of Skinvisible stock, and are not contracted to receive shares during the present period of coverage. We do not anticipate receiving shares either from the company or any third party.  Had we had shares, we avoid all potential conflicts of interest, as we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.  StockGuru is retained by Skinvisible for consulting purposes and investor awareness. We have received a total of six thousand two hundred dollars in payments. Previously for coverage in 2009, we were compensated and once held five hundred thousand shares of 144 restricted stock. We anticipate receiving up to six thousand dollars potentially over the next 180 days. We do not anticipate receiving shares of any kind, restricted or otherwise. StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030.